Liver Cirrhosis Pipeline Shows Strong Growth with 30+ Companies Advancing Novel Therapies Through Clinical Trials
核心洞察
DelveInsight's 2025 analysis reveals over 30 companies are actively developing more than 30 therapeutic candidates for liver cirrhosis, driven by rising global prevalence of liver diseases, particularly NAFLD associated with obesity and metabolic syndrome.
Sagimet Biosciences received FDA Breakthrough Therapy and Fast Track designations for denifanstat in February 2025, while Madrigal Pharmaceuticals plans to launch REZDIFFRA in Europe starting with Germany in the second half of 2025.
Multiple Phase III trials are progressing, including Akero Therapeutics' completed enrollment in the SYNCHRONY Real-World study with results expected in the first half of 2026, and ongoing ENLIGHTEN trials for MASH (搜索) cirrhosis.
The liver cirrhosis therapeutic landscape is experiencing unprecedented growth, with DelveInsight's 2025 pipeline analysis revealing more than 30 companies actively advancing over 30 therapeutic candidates through various stages of clinical development. This robust pipeline reflects the urgent need to address the increasing global burden of liver diseases, particularly nonalcoholic fatty liver disease (NAFLD), which is linked to rising obesity rates, alcohol consumption, and metabolic syndrome.
Regulatory Milestones Drive Market Momentum
February 2025 marked a significant regulatory milestone when the US FDA granted denifanstat both Breakthrough Therapy and Fast Track designations for non-cirrhotic MASH (搜索) with moderate-to-advanced fibrosis. Sagimet Biosciences disclosed lipidomic data from its Phase IIb FASCINATE-2 trial, examining triglyceride and LDL cholesterol profiles in patients with advanced fibrosis, with findings scheduled for presentation at the Keystone Symposium on MASH Pathogenesis and Therapeutics.
Madrigal Pharmaceuticals is positioning for a major European launch, planning to introduce REZDIFFRA in Europe beginning with Germany in the second half of 2025, pending EMA approval. If authorized, it would become the first approved therapy for MASH (搜索)-related liver fibrosis in Europe. Updated two-year MAESTRO-NAFLD-1 data released in February 2025 indicate potential clinical benefits in patients with compensated MASH cirrhosis, broadening its clinical applicability.
Phase III Programs Advance Toward Completion
Akero Therapeutics announced the completion of patient enrollment in its Phase III SYNCHRONY Real-World study for MASH (搜索)/MASLD (F1–F4) in January 2025, with results expected in the first half of 2026. The company reaffirmed strong momentum across its Phase III MASH programs and plans to release topline results from its first Phase III study by the end of 2025. Two additional Phase III trials—ENLIGHTEN-Fibrosis for non-cirrhotic MASH (F2–F3) and ENLIGHTEN-Cirrhosis for compensated MASH cirrhosis (F4)—are actively enrolling patients worldwide.
Diverse Therapeutic Approaches Show Promise
The pipeline encompasses a wide range of therapeutic modalities and mechanisms of action. Notable investigational therapies include Volixibat, VS-01, TVB-2640, TNP-2092, PRI-724, VE303, LPCN 1148, GXHPC1, Belapectin, RTX001, Elafibranor, and Zibotentan, progressing through various stages of clinical evaluation.
Galectin Therapeutics reported results from the NAVIGATE global clinical trial evaluating belapectin in patients with MASH (搜索) cirrhosis and portal hypertension in December 2024. Resolution Therapeutics (搜索), in partnership with the University of Edinburgh, showcased key RTX001 data at the EASL Congress 2024 in Milan in June 2024, highlighting the promise of macrophage cell therapy for advanced liver cirrhosis management.
Novel Cell-Based and Regenerative Approaches
The pipeline includes innovative cell-based therapies addressing end-stage disease. LyGenesis (搜索) announced dosing of the first patient in its Phase IIa trial evaluating a novel allogeneic regenerative cell therapy administered into lymph nodes for end-stage liver disease (ESLD) in April 2024. Lipocine presented Phase II data for LPCN 1148 in cirrhosis during a late-breaking oral session at the EASL Congress in Milan in June 2024, and reported encouraging topline results from its Phase II study in March 2024.
Comprehensive Pipeline Assessment
The therapeutic landscape spans multiple development stages, with assets categorized by product type (monotherapy, combination therapy), route of administration (intra-articular, intraocular, intrathecal, intravenous, oral, parenteral, subcutaneous, topical, transdermal), and molecular type (oligonucleotides, peptides, small molecules). Mechanisms of action include sodium-bile acid cotransporter inhibition, regulatory T-cell stimulation, ammonia scavenging, DNA gyrase inhibition, beta-catenin inhibition, CREB-binding protein inhibition, Wnt signaling pathway modulation, and microbiome modulation.
Market Drivers and Future Outlook
The liver cirrhosis treatment market is projected to witness substantial growth, driven by the increasing global prevalence of liver diseases, particularly NAFLD associated with rising obesity levels, alcohol consumption, and metabolic syndrome. Progress in antiviral therapies and regenerative medicine is enhancing clinical outcomes, while the aging population continues to fuel demand, collectively signaling a strong and rapidly evolving market outlook.
Key stakeholders in the liver cirrhosis space include Sagimet Biosciences, Gwo Xi Stem Cell Applied Technology, AstraZeneca, Galectin Therapeutics, Vedanta Biosciences, Resolution Therapeutics (搜索), Mirum Pharmaceuticals, TenNor Therapeutics, Prism Pharma, Ipsen, Versantis AG, and Lipocine, among others, representing a diverse ecosystem of pharmaceutical innovators addressing this significant unmet medical need.